MCF Advisors LLC Boosts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

MCF Advisors LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 45.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,779 shares of the biopharmaceutical company’s stock after purchasing an additional 2,111 shares during the quarter. MCF Advisors LLC’s holdings in Gilead Sciences were worth $626,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Fort Washington Investment Advisors Inc. OH grew its position in Gilead Sciences by 16.6% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 376,047 shares of the biopharmaceutical company’s stock valued at $34,735,000 after buying an additional 53,617 shares during the last quarter. Atomi Financial Group Inc. boosted its holdings in shares of Gilead Sciences by 36.7% in the fourth quarter. Atomi Financial Group Inc. now owns 8,312 shares of the biopharmaceutical company’s stock valued at $768,000 after acquiring an additional 2,231 shares in the last quarter. LifePlan Financial LLC increased its stake in shares of Gilead Sciences by 9.2% during the fourth quarter. LifePlan Financial LLC now owns 5,987 shares of the biopharmaceutical company’s stock worth $553,000 after acquiring an additional 504 shares during the period. Lmcg Investments LLC raised its holdings in Gilead Sciences by 0.6% during the fourth quarter. Lmcg Investments LLC now owns 103,025 shares of the biopharmaceutical company’s stock worth $9,516,000 after purchasing an additional 650 shares in the last quarter. Finally, Brookmont Capital Management lifted its position in Gilead Sciences by 16.7% in the fourth quarter. Brookmont Capital Management now owns 51,083 shares of the biopharmaceutical company’s stock valued at $4,719,000 after purchasing an additional 7,322 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.2 %

Shares of NASDAQ GILD opened at $92.96 on Wednesday. The firm’s 50 day moving average price is $91.65 and its 200 day moving average price is $84.38. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market cap of $115.85 billion, a P/E ratio of 1,032.89, a price-to-earnings-growth ratio of 1.29 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.29 earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock valued at $42,130,461 over the last quarter. Company insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Truist Financial boosted their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Piper Sandler upped their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Royal Bank of Canada reissued a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.